Literature DB >> 24211413

Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms.

Paola Lecca1.   

Abstract

We review recent Bayesian network inference methodologies we developed to infer genetic and metabolic pathways associated to oncological drug chemoresistance. Bayesian inference is supported by a rigorous and widely accepted mathematical formalization of predictive analytics. It is an inherently integrative approach allowing the incorporation of prior knowledge and constraints. Moreover, it is recommended to treat noisy data, and large amount of data whose dynamics laws are mostly unknown. We focus on variational Bayesian methods for the inference of stochastic reaction processes and we present a compendium of the recent results of inference of gene and metabolic networks presiding at the development of pancreas cancer resistance to gemcitabine.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24211413     DOI: 10.1016/j.drudis.2013.10.026

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  7 in total

Review 1.  CANDO and the infinite drug discovery frontier.

Authors:  Mark Minie; Gaurav Chopra; Geetika Sethi; Jeremy Horst; George White; Ambrish Roy; Kaushik Hatti; Ram Samudrala
Journal:  Drug Discov Today       Date:  2014-06-26       Impact factor: 7.851

2.  [Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis].

Authors:  Nannan Tian; Lei Zhou; Danni Yang; Huanxian Wu; Yunci Ma; Lin Lü; Shaoyu Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

3.  Structure and properties of slow-resorbing nanofibers obtained by (co-axial) electrospinning as tissue scaffolds in regenerative medicine.

Authors:  Andrzej Hudecki; Joanna Gola; Saeid Ghavami; Magdalena Skonieczna; Jarosław Markowski; Wirginia Likus; Magdalena Lewandowska; Wojciech Maziarz; Marek J Los
Journal:  PeerJ       Date:  2017-12-18       Impact factor: 2.984

4.  Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo.

Authors:  Shuhei Shinoda; Seiji Kaino; Shogo Amano; Hirofumi Harima; Toshihiko Matsumoto; Koichi Fujisawa; Taro Takami; Naoki Yamamoto; Takahiro Yamasaki; Isao Sakaida
Journal:  Oncotarget       Date:  2018-06-19

5.  Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.

Authors:  Kun Fan; Zhiyao Fan; He Cheng; Qiuyi Huang; Chao Yang; Kaizhou Jin; Guopei Luo; Xianjun Yu; Chen Liu
Journal:  Cancer Med       Date:  2019-08-19       Impact factor: 4.452

6.  Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer.

Authors:  Ming Zhan; Hui Wang; Sun-Wang Xu; Lin-Hua Yang; Wei Chen; Shuang-Xia Zhao; Hui Shen; Qiang Liu; Rui-Meng Yang; Jian Wang
Journal:  EBioMedicine       Date:  2019-10-04       Impact factor: 8.143

Review 7.  Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.

Authors:  Zhe Chen; Yuanqiang Zheng; Yanchun Shi; Zhengrong Cui
Journal:  Int J Nanomedicine       Date:  2018-01-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.